表紙
市場調査レポート

核医学/放射性医薬品の北米市場の予測 〜2020年:タイプ (診断用 (SPECT, PET)・治療用 (ベータ放射体, アルファ放射体, 小線源治療))・用途別

North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), by Application (Oncology, Cardiology) - Forecasts to 2020

発行 MarketsandMarkets 商品コード 354059
出版日 ページ情報 英文 181 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
核医学/放射性医薬品の北米市場の予測 〜2020年:タイプ (診断用 (SPECT, PET)・治療用 (ベータ放射体, アルファ放射体, 小線源治療))・用途別 North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), by Application (Oncology, Cardiology) - Forecasts to 2020
出版日: 2016年03月09日 ページ情報: 英文 181 Pages
概要

世界の核医学/放射性医薬品の市場は2015年から2020年にかけて8.6%のCAGR (複合年間成長率) で推移し、2015年の19億7000万米ドルから、2020年には29億8000万米ドルの規模に成長すると予測されています。

当レポートでは、世界の核医学/放射性医薬品の市場について調査し、市場の定義と概要、市場成長への影響因子および市場機会の分析、パイプラインの評価、診断/治療区分・検査区分・薬剤タイプ・対象疾患など各種区分別の動向と市場規模の推移と予測、診断および治療的処置件数の推移と予測、国別の動向、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

  • イントロダクション
  • 現在のシナリオ
  • 将来の展望

第4章 重要考察

  • 北米の核医学/放射性医薬品市場
  • 国別市場
  • タイプ別市場の実績・予測

第5章 市場概要

  • イントロダクション
  • 市場区分
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題

第6章 市場分析:パイプライン評価

  • イントロダクション
  • 診断用ラジオアイソトープ
  • 治療用ラジオアイソトープ

第7章 市場分析:タイプ別

  • イントロダクション
  • 診断部門
    • SPECT用放射性医薬品
      • テクネチウム99m
      • タリウム201
      • ガリウム67
      • ヨウ素123
      • その他のSPECT用アイソトープ
    • PET用放射性医薬品
      • フッ素18
      • ルビジウム82
      • その他のPET用アイソトープ
  • 治療部門
    • ベータ放射体
      • ヨウ素131
      • イットリウム90
      • サマリウム153
      • レニウム186
      • ルテチウム177
      • その他のベータ放射体用アイソトープ
    • アルファ放射体
      • ラジウム223
    • 小線源治療
      • ヨウ素125
      • イリジウム192
      • パラジウム103
      • セシウム131
      • その他の小線源治療用アイソトープ

第8章 市場分析:用途別

  • イントロダクション
  • 診断部門
    • SPECT用
      • 心臓
      • リンパ腫
      • 神経
      • 甲状腺
      • その他
    • PET用
      • 心臓
      • 神経
      • その他
  • 治療部門
    • 甲状腺
    • 骨転移
    • リンパ腫
    • 内分泌腫瘍
    • その他

第9章 処置件数

  • イントロダクション
  • 診断処置件数
    • SPECT用放射性医薬品を用いた診断処置件数
    • PET用放射性医薬品を用いた診断処置件数
  • 治療処置件数
    • ベータ放射体を用いた治療処置件数
    • 小線源治療件数

第10章 国別分析

  • イントロダクション
  • 診断部門
    • 北米
      • 米国
      • カナダ
  • 治療部門
    • 北米
      • 米国
      • カナダ

第11章 競合環境

  • 概要
  • 競合状況・動向
    • イントロダクション
    • 合意・提携・契約・協力
    • 販促
    • 新製品の投入
    • 拡張
    • 買収
    • その他
  • 成功戦略の実証的評価
    • 戦略的成長のルート:有機的・無機的成長戦略
    • 無機的成長戦略
    • 無機的成長戦略

第12章 企業プロファイル

  • イントロダクション
  • CARDINAL HEALTH, INC.
  • MALLINCKRODT PLC
  • GE HEALTHCARE
  • LANTHEUS MEDICAL IMAGING, INC.
  • BAYER HEALTHCARE
  • BRACCO IMAGING S.P.A
  • ECZACIBASI-MONROL NUCLEAR PRODUCTS
  • NORDION, INC.
  • ADVANCED ACCELERATOR APPLICATIONS S.A.
  • IBA MOLECULAR IMAGING
    • 財務動向
    • 製品・サービス
    • 戦略
    • 近年の発展動向、など

第13章 付録

図表

目次
Product Code: BT 4151

The North American nuclear medicine/radiopharmaceuticals market is poised to reach USD 2.98 billion by 2020 from USD 1.97 billion in 2015, growing at a CAGR of 8.6% during the forecast period of 2015 to 2020.

Nuclear medicine is a specialized field of medicine that covers all aspects of the use of radioactive substances, through either injection or ingestion, for the diagnosis or treatment of diseases such as cancer, cardiovascular disease, and neurological diseases. The nuclear medicine/radiopharmaceuticals market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, whereas radiopharmaceuticals in the therapeutics market are categorized as beta emitters, brachytherapy isotopes, and alpha emitters.

In 2015, the diagnostic segment accounted for the largest share of the North American nuclear medicine/radiopharmaceuticals market, by type. Moreover, the SPECT segment is expected to account for the largest share of the North American diagnostic nuclear medicine/radiopharmaceuticals market. This can be attributed to growing cancer patient population, increasing preference for SPECT procedures, advances in SPECT radioisotopes, and cyclotron-based Tc-99m generation. In addition, in 2015, the beta emitters segment is expected to account for the largest share of the North American therapeutic nuclear medicine/radiopharmaceuticals market, owing to heavy funding for research on beta emitters, new therapeutic radioisotopes, and reimbursement policies in favor of using radiopharmaceuticals for cancer therapy.

In 2015, the cardiology application accounts for the largest share of North American nuclear medicine/radiopharmaceuticals market for SPECT applications. This large share can be attributed to new hardware and software designs in SPECT, rising incidence rate of CVDs, and adoption of SPECT in new cardiac applications. The PET market is dominated by oncology applications owing to its accuracy, and preference of PET over conventional imaging. In 2015, the therapeutic market is dominated by thyroid applications. This large share of thyroid applications can be attributed to the factors such as non-invasive method for treatment, and growing incidence of thyroid cancer.

In 2015, U.S. is expected to account for the largest share of the North American nuclear medicine/radiopharmaceuticals market, followed by Canada. The U.S. market is also likely to witness the highest growth rate of the North American nuclear medicine/radiopharmaceuticals market in the coming years. The U.S.'s large share and high growth rate can be attributed to the focus on domestic production of Mo-99, the approval of new radiopharmaceuticals by the FDA in the U.S., FDA approval for alpha emitter, growing focus on therapeutic nuclear medicine as an alternative treatment in oncology, and growing incidence of thyroid cancer.

The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (agreements, collaborations, contracts, and partnerships, marketing and promotions, new product launches, expansions, acquisitions, funding and grants, patent coverage extensions, website launches, and license renewals) to increase their market shares and establish a strong foothold in the North American market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of top players in the North American nuclear medicine/radiopharmaceuticals market. The report analyzes the North American nuclear medicine/radiopharmaceuticals, by type of isotopes, applications, and country
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the North American nuclear medicine/radiopharmaceuticals market
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various nuclear medicine products, applications, and technologies across countries
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the North American nuclear medicine/radiopharmaceuticals market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the North American nuclear medicine/radiopharmaceuticals market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. Key industry insights
      • 2.2.2.2. Key data from primary sources
      • 2.2.2.3. Key Insights from primary sources
  • 2.3. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.4. RESEARCH DESIGN
  • 2.5. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.6. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK

4. PREMIUM INSIGHTS

  • 4.1. NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET
  • 4.2. NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS DIAGNOSTIC MARKET, BY THERAPEUTIC AND SPECT APPLICATION
  • 4.3. NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY COUNTRY
  • 4.4. NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY TYPE (2015 VS. 2020)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Increasing preference for SPECT and PET scans
      • 5.3.1.2. Alpha radioimmunotherapy-based targeted cancer treatment
      • 5.3.1.3. Advances in radiotracers
      • 5.3.1.4. Growing incidence of cancer and CVDs
      • 5.3.1.5. Rising awareness about the effective use of radiopharmaceuticals in various applications
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Requirement of high capital investments to limit the procurement of scanners
      • 5.3.2.2. Shorter half-life of radiopharmaceuticals
      • 5.3.2.3. Stringent regulatory guidelines and Good Manufacturing Practices
      • 5.3.2.4. Competition from conventional diagnostic procedures
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Upcoming radioisotopes
      • 5.3.3.2. Alternative diagnostic radiopharmaceutical solutions
      • 5.3.3.3. Cyclotron-based production
      • 5.3.3.4. Use of radiopharmaceuticals in neurological applications
    • 5.3.4. CHALLENGES
      • 5.3.4.1. Shutdown of nuclear reactors to impact production of radioisotopes

6. NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET: PIPELINE ASSESSMENT

  • 6.1. INTRODUCTION
  • 6.2. DIAGNOSTIC RADIOISOTOPES
  • 6.3. THERAPEUTIC RADIOISOTOPES

7. NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
    • 7.2.1. SPECT RADIOPHARMACEUTICALS
      • 7.2.1.1. Technetium-99m
      • 7.2.1.2. Thallium-201
      • 7.2.1.3. Gallium-67
      • 7.2.1.4. Iodine-123
      • 7.2.1.5. Other SPECT Isotopes
    • 7.2.2. PET RADIOPHARMACEUTICALS
      • 7.2.2.1. Fluorine-18
      • 7.2.2.2. Rubidium-82
      • 7.2.2.3. Other PET Isotopes
  • 7.3. THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
    • 7.3.1. BETA EMITTERS
      • 7.3.1.1. Iodine-131
      • 7.3.1.2. Yttrium-90
      • 7.3.1.3. Samarium-153
      • 7.3.1.4. Rhenium-186
      • 7.3.1.5. Lutetium-177
      • 7.3.1.6. Other Beta Emitter Isotopes
    • 7.3.2. ALPHA EMITTERS
      • 7.3.2.1. Radium-223
    • 7.3.3. BRACHYTHERAPY
      • 7.3.3.1. Iodine-125
      • 7.3.3.2. Iridium-192
      • 7.3.3.3. Palladium-103
      • 7.3.3.4. Cesium-131
      • 7.3.3.5. Other Brachytherapy Isotopes

8. NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. DIAGNOSTIC APPLICATIONS
    • 8.2.1. SPECT APPLICATIONS
      • 8.2.1.1. Cardiology
      • 8.2.1.2. Lymphoma
      • 8.2.1.3. Neurology
      • 8.2.1.4. Thyroid
      • 8.2.1.5. Other SPECT Applications
    • 8.2.2. PET APPLICATIONS
      • 8.2.2.1. Oncology
      • 8.2.2.2. Cardiology
      • 8.2.2.3. Neurology
      • 8.2.2.4. Other PET Applications
  • 8.3. THERAPEUTIC APPLICATIONS
    • 8.3.1. THYROID
    • 8.3.2. BONE METASTASIS
    • 8.3.3. LYMPHOMA
    • 8.3.4. ENDOCRINE TUMORS
    • 8.3.5. OTHER THERAPEUTIC APPLICATIONS

9. NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME

  • 9.1. INTRODUCTION
  • 9.2. DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME
    • 9.2.1. SPECT RADIOPHARMACEUTICALS
    • 9.2.2. PET RADIOPHARMACEUTICALS
  • 9.3. THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME
    • 9.3.1. BETA EMITTERS
    • 9.3.2. BRACHYTHERAPY

10. NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY COUNTRY

  • 10.1. INTRODUCTION
  • 10.2. DIAGNOSTIC MARKET
    • 10.2.1. NORTH AMERICA
      • 10.2.1.1. U.S.
        • 10.2.1.1.1. DOMESTIC PRODUCTION OF MO-99 IN THE U.S.
        • 10.2.1.1.2. APPROVAL OF NEW RADIOPHARMACEUTICALS BY FDA
      • 10.2.1.2. CANADA
        • 10.2.1.2.1. EXTENSION OF OPERATIONS AT THE CANADIAN NATIONAL RESEARCH UNIVERSAL (NRU) REACTOR
        • 10.2.1.2.2. ALTERNATIVE MEDICAL ISOTOPE TECHNOLOGIES IN CANADA
  • 10.3. THERAPEUTIC MARKET
    • 10.3.1. NORTH AMERICA
      • 10.3.1.1. U.S.
        • 10.3.1.1.1. FDA APPROVAL FOR ALPHA EMITTER
        • 10.3.1.1.2. THERAPEUTIC NUCLEAR MEDICINE - ALTERNATIVE TREATMENT CHOICE IN ONCOLOGY
        • 10.3.1.1.3. GROWING INCIDENCE OF THYROID CANCER
      • 10.3.1.2. CANADA
        • 10.3.1.2.1. EXPERTISE IN ISOTOPE PRODUCTION
        • 10.3.1.2.2. GOVERNMENT INITIATIVES TO INCREASE THE NUMBER OF NUCLEAR MEDICINE TREATMENT CENTERS
        • 10.3.1.2.3. HIGH INCIDENCE OF CANCER

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. COMPETITIVE SITUATION AND TRENDS
    • 11.2.1. INTRODUCTION
    • 11.2.2. AGREEMENTS, COLLABORATIONS, CONTRACTS, AND PARTNERSHIPS
    • 11.2.3. MARKETING AND PROMOTIONS
    • 11.2.4. NEW PRODUCT LAUNCHES
    • 11.2.5. EXPANSIONS
    • 11.2.6. ACQUISITIONS
    • 11.2.7. OTHER STRATEGIES
  • 11.3. NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: EMPIRICAL ASSESSMENT OF GROWTH STRATEGIES
    • 11.3.1. ROUTE TO STRATEGIC GROWTH: ORGANIC AND INORGANIC GROWTH STRATEGIES
    • 11.3.2. ORGANIC GROWTH STRATEGIES
    • 11.3.3. INORGANIC GROWTH STRATEGIES

12. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 12.1. INTRODUCTION
  • 12.2. CARDINAL HEALTH, INC.
  • 12.3. MALLINCKRODT PLC
  • 12.4. GE HEALTHCARE
  • 12.5. LANTHEUS MEDICAL IMAGING, INC.
  • 12.6. BAYER HEALTHCARE
  • 12.7. BRACCO IMAGING S.P.A
  • 12.8. ECZACIBASI-MONROL NUCLEAR PRODUCTS
  • 12.9. NORDION, INC.
  • 12.10. ADVANCED ACCELERATOR APPLICATIONS S.A.
  • 12.11. IBA MOLECULAR IMAGING

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. DISCUSSION GUIDE
  • 13.2. AVAILABLE CUSTOMIZATIONS
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: ALPHA RADIOIMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT DRIVING MARKET GROWTH
  • TABLE 2: REQUIREMENT OF HIGH CAPITAL INVESTMENTS AND SHORT HALF-LIFE OF RADIOPHARMACEUTICALS RESTRAINING MARKET GROWTH
  • TABLE 3: POTENTIAL RADIOISOTOPES IN THE PIPELINE TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES TO MARKET PLAYERS
  • TABLE 4: SHUTDOWN OF NUCLEAR REACTORS IS A MAJOR CHALLENGE IN THIS MARKET
  • TABLE 5: DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING DIAGNOSTIC APPLICATIONS
  • TABLE 6: DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING THERAPEUTIC APPLICATIONS
  • TABLE 7: NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 8: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 9: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 10: NORTH AMERICA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 11: NORTH AMERICA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE, 2013-2020 (USD MILLION)
  • TABLE 12: NORTH AMERICA: TECHNETIUM-99M NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 13: NORTH AMERICA: THALLIUM-201 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 14: NORTH AMERICA: GALLIUM-67 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 15: NORTH AMERICA: IODINE-123 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 16: NORTH AMERICA: OTHER SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 17: NORTH AMERICA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 18: NORTH AMERICA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE, 2013-2020 (USD MILLION)
  • TABLE 19: NORTH AMERICA: FLUORINE-18 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 20: NORTH AMERICA: RUBIDIUM-82 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 21: NORTH AMERICA: OTHER PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 22: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 23: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 24: NORTH AMERICA: BETA EMITTER NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 25: NORTH AMERICA: BETA EMITTER NUCLEAR MEDICINE MARKET SIZE, BY ISOTOPE, 2013-2020 (USD MILLION)
  • TABLE 26: NORTH AMERICA: IODINE-131 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 27: NORTH AMERICA: YTTRIUM-90 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 28: NORTH AMERICA: SAMARIUM-153 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 29: NORTH AMERICAN RHENIUM-186 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 30: NORTH AMERICA: LUTETIUM-177 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 31: NORTH AMERICA: OTHER BETA EMITTER NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 32: NORTH AMERICA: ALPHA EMITTER NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 33: NORTH AMERICA: BRACHYTHERAPY NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 34: NORTH AMERICA: BRACHYTHERAPY NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE, 2013-2020 (USD MILLION)
  • TABLE 35: NORTH AMERICA: IODINE-125 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 36: NORTH AMERICA: IRIDIUM-192 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 37: NORTH AMERICA: PALLADIUM-103 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 38: NORTH AMERICA: CESIUM-131 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 39: NORTH AMERICA: OTHER BRACHYTHERAPY NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 40: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS APPLICATIONS MARKET SIZE FOR SPECT ISOTOPES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 41: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS APPLICATIONS MARKET SIZE FOR SPECT ISOTOPES, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 42: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 43: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 44: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 45: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 46: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 47: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 48: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 49: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ONCOLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 50: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 51: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 52: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 53: NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 54: NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 55: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 56: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BONE METASTASIS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 57: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 58: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ENDOCRINE APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 59: NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 60: NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS)
  • TABLE 61: NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY COUNTRY, 2013-2020 (THOUSAND UNITS)
  • TABLE 62: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS)
  • TABLE 63: NORTH AMERICA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS)
  • TABLE 64: NORTH AMERICA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS)
  • TABLE 65: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS)
  • TABLE 66: NORTH AMERICA: BETA EMITTERS NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS)
  • TABLE 67: NORTH AMERICA: BRACHYTHERAPY NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS)
  • TABLE 68: NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 69: U.S.: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 70: U.S.: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 71: U.S.: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 72: U.S.: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 73: U.S.: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 74: CANADA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 75: CANADA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 76: CANADA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 77: CANADA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 78: CANADA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 79: U.S.: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 80: U.S.: BETA EMITTERS NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 81: U.S.: BRACHYTHERAPY NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 82: U.S.: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 83: CANADA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 84: CANADA: BETA EMITTERS NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 85: CANADA: BRACHYTHERAPY NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 86: CANADA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 87: AGREEMENTS, COLLABORATIONS, CONTRACTS, AND PARTNERSHIPS, 2013-2016
  • TABLE 88: MARKETING AND PROMOTIONS, 2013-2016
  • TABLE 89: NEW PRODUCT LAUNCHES, 2013-2016
  • TABLE 90: EXPANSIONS, 2013-2014
  • TABLE 91: ACQUISITIONS, 2013-2016
  • TABLE 92: OTHER STRATEGIES, 2013-2016

LIST OF FIGURES

  • FIGURE 1: NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION
  • FIGURE 2: NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 3: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 4: BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND COUNTRY
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 6: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 7: RESEARCH DESIGN
  • FIGURE 8: DATA TRIANGULATION METHODOLOGY
  • FIGURE 9: THERAPEUTICS MARKET TO WITNESS THE HIGHEST GROWTH RATE FROM 2015 TO 2020
  • FIGURE 10: NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTICS MARKET SHARE, BY TYPE, 2015 VS. 2020
  • FIGURE 11: GEOGRAPHICAL SNAPSHOT OF THE NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, 2015
  • FIGURE 12: NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS SPECT APPLICATIONS MARKET SIZE, 2015 VS. 2020 (USD MILLION)
  • FIGURE 13: ADVANCES IN RADIOTRACERS TO PROPEL MARKET GROWTH
  • FIGURE 14: THYROID APPLICATION SEGMENT DOMINATES THE NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET IN 2015
  • FIGURE 15: U.S. TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 16: DIAGNOSTICS SEGMENT TO COMMAND THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD
  • FIGURE 17: NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION
  • FIGURE 18: NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 19: CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES, BY PHASE
  • FIGURE 20: CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES, BY COMPANY & INSTITUTE
  • FIGURE 21: CLINICAL TRIALS FOR RADIOISOTOPES, BY TYPE
  • FIGURE 22: CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY SUBTYPE
  • FIGURE 23: CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY INDICATION
  • FIGURE 24: CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY PHASE
  • FIGURE 25: CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY COMPANY & INSTITUTE
  • FIGURE 26: CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY SUBTYPE
  • FIGURE 27: CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY INDICATION
  • FIGURE 28: CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY PHASE
  • FIGURE 29: CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY COMPANY & INSTITUTE
  • FIGURE 30: NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION, BY TYPE
  • FIGURE 31: THERAPEUTIC SEGMENT TO GROW AT THE HIGHEST CAGR OF 10.0%
  • FIGURE 32: PET SEGMENT TO GROW AT THE HIGHEST CAGR OF 11.3% DURING THE FORECAST PERIOD
  • FIGURE 33: ALPHA EMITTERS SEGMENT TO GROW AT THE HIGHEST CAGR OF 16.8% DURING THE FORECAST PERIOD
  • FIGURE 34: NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS APPLICATIONS MARKET SEGMENTATION
  • FIGURE 35: SEGMENTATION OF NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS APPLICATIONS MARKET FOR SPECT ISOTOPES
  • FIGURE 36: U.S. TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 37: NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 7.8% DURING THE FORECAST PERIOD
  • FIGURE 38: SEGMENTATION OF NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS APPLICATIONS MARKET FOR PET ISOTOPES
  • FIGURE 39: U.S. TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 40: NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 12.6% DURING THE FORECAST PERIOD
  • FIGURE 41: NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS APPLICATIONS MARKET SEGMENTATION
  • FIGURE 42: U.S. TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 43: ENDOCRINE TUMORS APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 10.8% DURING THE FORECAST PERIOD
  • FIGURE 44: U.S. TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET IN 2015
  • FIGURE 45: NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET OVERVIEW
  • FIGURE 46: U.S. TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET IN 2015
  • FIGURE 47: NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET OVERVIEW
  • FIGURE 48: TOP 5 STRATEGIES ADOPTED BY PLAYERS OVER THE LAST THREE YEARS (2013-2016)
  • FIGURE 49: BATTLE FOR MARKET SHARE: AGREEMENTS, COLLABORATIONS, CONTRACTS, AND PARTNERSHIPS WAS THE KEY STRATEGY (2013 -2016)
  • FIGURE 50: ORGANIC & INORGANIC GROWTH STRATEGIES: INDUSTRY TREND VS. KEY PLAYERS
  • FIGURE 51: ORGANIC GROWTH STRATEGIES, BY KEY PLAYER (2013-2016)
  • FIGURE 52: INORGANIC GROWTH STRATEGIES, BY KEY PLAYER (2013-2016)
  • FIGURE 53: PRODUCT MIX OF THE KEY PLAYERS IN THE MARKET
  • FIGURE 54: CARDINAL HEALTH, INC.: COMPANY SNAPSHOT
  • FIGURE 55: MALLINCKRODT PLC: COMPANY SNAPSHOT
  • FIGURE 56: GE HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 57: LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT
  • FIGURE 58: BAYER HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 59: NORDION, INC.: COMPANY SNAPSHOT
  • FIGURE 60: ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT
Back to Top